
## Gopal Sapparapu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2236465/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature, 2016, 540, 443-447.	27.8	349
2	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell, 2016, 164, 392-405.	28.9	160
3	A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Science Immunology, 2019, 4, .	11.9	147
4	Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell, 2016, 167, 684-694.e9.	28.9	141
5	Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. Cell, 2015, 160, 893-903.	28.9	130
6	A human antibody against Zika virus crosslinks the E protein to prevent infection. Nature Communications, 2017, 8, 14722.	12.8	122
7	Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host and Microbe, 2015, 18, 86-95.	11.0	116
8	Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region. Nature Microbiology, 2018, 3, 670-677.	13.3	68
9	Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action. Journal of Infectious Diseases, 2017, 215, 1124-1131.	4.0	65
10	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. Journal of Clinical Investigation, 2016, 126, 1482-1494.	8.2	62
11	Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore. PLoS ONE, 2013, 8, e61101.	2.5	51
12	Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13898-13903.	7.1	50
13	Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site. Journal of Virology, 2016, 90, 780-789.	3.4	50
14	Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. Journal of Virology, 2017, 91, .	3.4	44
15	Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5830-E5837.	7.1	41
16	Exceptional Amyloid β Peptide Hydrolyzing Activity of Nonphysiological Immunoglobulin Variable Domain Scaffolds. Journal of Biological Chemistry, 2008, 283, 36724-36733.	3.4	36
17	Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. MBio, 2018, 9, .	4.1	32
18	Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. Journal of Clinical Investigation, 2013, 123, 4405-4409.	8.2	31

GOPAL SAPPARAPU

#	Article	IF	CITATIONS
19	Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. Journal of Clinical Investigation, 2015, 125, 2523-2531.	8.2	31
20	Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding. PLoS Pathogens, 2016, 12, e1005719.	4.7	27
21	Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9346-9351.	7.1	26
22	A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Nature Microbiology, 2019, 4, 71-77.	13.3	25
23	Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6. Journal of Immunology, 2016, 197, 1065-1073.	0.8	21
24	Long antibody HCDR3s from HIV-naÃ <sup>-</sup> ve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4446-4451.	7.1	20
25	Recognition of influenza H3N2 variant virus by human neutralizing antibodies. JCI Insight, 2016, 1, .	5.0	20
26	Constant Domain-regulated Antibody Catalysis*. Journal of Biological Chemistry, 2012, 287, 36096-36104.	3.4	14
27	Antigen-specific Proteolysis by Hybrid Antibodies Containing Promiscuous Proteolytic Light Chains Paired with an Antigen-binding Heavy Chain. Journal of Biological Chemistry, 2009, 284, 24622-24633.	3.4	13
28	Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling. Journal of Clinical Investigation, 2019, 130, 315-328.	8.2	11
29	Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. PLoS ONE, 2018, 13, e0209437.	2.5	8
30	Intracellular neutralization of a virus using a cell-penetrating molecular transporter. Nanomedicine, 2014, 9, 1613-1624.	3.3	7
31	Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. Aids, 2014, 28, 2201-2211.	2.2	4
32	Human Monoclonal Antibodies to the Staphylococcus aureus Toxin LukAB have Distinct Mechanisms of Protection and Are Efficacious In Vivo. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
33	Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. Journal of Clinical Investigation, 2013, 123, 4979-4979.	8.2	0